TMO Quantitative Stock Analysis

According to Validea's guru fundamental report, Thermo Fisher Scientific (TMO) exhibits strong fundamentals based on the investment strategy of John Neff's Low PE Investor model, receiving a 62% rating. The analysis indicates the firm passes criteria related to EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence, but fails tests for P/E ratio and total return/PE, suggesting a mixed valuation profile despite solid growth characteristics.

Analysis

Thermo Fisher Scientific Inc. (TMO), a large-cap growth stock within the Medical Equipment & Supplies sector, received a 62% rating from Validea's Low PE Investor model, which is based on John Neff's published strategy. This score indicates that while the firm shows some positive attributes, it does not meet the 80% threshold for "some interest" or the 90% level for "strong interest" typically sought by this specific investment model. TMO demonstrates strength in several fundamental areas, passing criteria for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence. However, it fails the model's tests for P/E ratio and total return/PE. This suggests that while TMO exhibits persistent earnings growth, a key component of Neff's strategy, its current market valuation does not align with the model's requirement for a discount relative to its earnings growth and dividend yield, leading to a mixed assessment under this particular framework.

Key Decisions for Investors

• Investors should note TMO's strong fundamental characteristics, particularly its consistent EPS and sales growth, positive future EPS growth outlook, and robust free cash flow generation.
• The stock's current P/E ratio and total return/PE metrics fail the John Neff Low PE Investor model's criteria, suggesting that from this specific value investing perspective, TMO may not be sufficiently undervalued despite its operational strengths.
• Consider that while TMO does not fully align with Neff's value strategy due to valuation concerns, its positive growth and persistence metrics might warrant further investigation for investors with different criteria or a belief that its growth justifies the current premium.